3. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 2023;389:1935-48. 4. Saw SPL, Le X, Hendriks LEL, Remon J. New treatment options for patients with oncogen...
以EGFR为靶标的非小细胞肺癌中药天然产物抑制剂的虚拟筛选 肺癌作为世界上最常见的恶性肿瘤之一,已成为我国城市人口恶性肿瘤死亡原因的第一位[1],其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占肺癌总数的85%,5年生存率只有21%[2]...
Borgeaud M, et al., Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review, Journal of Thoracic Oncology (2024).
近日,来自英国剑桥大学的Giulia Biffi团队在Cancer Cell上在线发表题为EGFR-activated myofibroblasts promote metastasis of pancreatic cancer的文章,证实PDAC myCAF中存在着EGFR/ ERBB2信号的激活,其是通过双调节蛋白介导的自分泌过程而在myCAF中被PDAC恶性细胞分泌的TGF-β所诱导的,而EGFR激活的myCAF可促进PDAC小鼠的...
近日,来自英国剑桥大学的Giulia Biffi团队在Cancer Cell上在线发表题为EGFR-activated myofibroblasts promote metastasis of pancreatic cancer的文章,证实PDAC myCAF中存在着EGFR/ ERBB2信号的激活,其是通过双调节蛋白介导的自分泌过程而在myCAF中被PDAC恶性细胞分泌的TGF-β所诱导的,而EGFR激活的myCAF可促进PDAC小鼠的...
[12] Saito G , Ebata T , Ishiwata T , et al. Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents[J]. Supportive Care in Cancer, 2021, 29(7).
参考文献: Borgeaud M, et al., Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review, Journal of Thoracic Oncology (2024).
[9]NCCN Guidelines Version 1.2022 Non-Small Cell Lung Cancer. [10]Yun J,Lee SH,Kim SY,et al.Antitumor Activity of Amivantamab(JNJ-61186372),an EGFR-MET Bispecific Antibody,in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Cancer Discov.2020;10(8):1194-1209.doi:10.1158/2159-8290....
Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases. Transl Lung Cancer Res. 2023 Nov 30;12(11):2330-2341. doi: 10.21037...
9.Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. The Lancet Oncology, 2019, 20(...